Data on chronic liver disease treatment to be presented at annual AASLD meeting: 3 highlights


Data related to obeticholic acid will be presented at the American Association for the Study of Liver Diseases' annual meeting, according to New York-based biopharmaceutical company Intercept Pharmaceuticals.

Obeticholic acid, commercially known as Ocaliva, is a prescription medication developed by Intercept Pharmaceuticals for the treatment of primary biliary cholangitis.

Here are three of the upcoming presentations:

1. "Predicted Risk of End Stage Liver Disease with Continued Standard of Care and Subsequent Addition of Obeticholic Acid in Patients with PBC"

2. "Long-Term Effect of Obeticholic Acid on Transient Elastography and AST to Platelet Ratio Index in Patients with PBC"

3. "Obeticholic acid, a synthetic FXR agonist, prevents hepatic inflammation and fibrosis in a novel mouse model of non-alcoholic steatohepatitis"

There will be a total of 11 presentations on obeticholic acid at the meeting.

© Copyright ASC COMMUNICATIONS 2021. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Featured Webinars

Featured Whitepapers